CSafe Global Expands EWR Service Center to Facilitate Triple Volume Business

Dayton, OH Mar 15, 2016 – CSafe Global, the leading manufacturer of temperature-controlled air-freight containers for the biopharmaceutical industry, announces the expansion of their Newark EWR Service Center.
Part of an exciting growth strategy, this latest investment will enable CSafe Global to meet the growing customer demand for the CSafe RKN while establishing the foundation for the expansion of CSafe’s passive product line in the Northeast. In 2015, service centers were established in San Francisco and Los Angeles. In 2016, the company will be adding seven centers in key global locations.
Rick Rackley, Director of Quality, Technical Support and Service Partners at CSafe, provides the rationale behind the expansion: “Our experienced teams of technicians are trained in-house to a very high standard with CSafe Global’s products and processes to facilitate the increasing volume of business, reduce turn time and ensure availability.”
Brian Kohr, President and CEO of CSafe Global expands on Rick’s comments by adding: “CSafe Global continues to uphold its declared vision of being the most trusted name in cold chain solutions. Although expanded to twice the previous size, the EWR service center is tooled up in processes and equipment to handle three times the current volume of active containers. In 2016, we will also add service points in Tokyo NRT, Atlanta ATL, Rome FCO, Vienna VIE and Brussels BRU, making it a banner year for our growing network. This highlights the dedication of the CSafe team to helping ensure continued successful shipments for our customers. We will continue to ensure the CSafe brand is associated with the highest levels of customer and technical support and maintenance.”

HealthTronics Acquires United Therapies

New York, NY: Altaris Capital Partners, LLC is pleased to announce that its portfolio company, HealthTronics, Inc., has acquired Chicago-based United Therapies, LLC.
Founded in 1985, United Therapies provides mobile lithotripsy and laser technology to healthcare providers across the United States. The acquisition not only broadens HealthTronics’ geographic presence, but also enables more doctors and hospitals to offer high quality and cost effective clinical treatments using lithotripsy, microwave ablation, nerve monitoring, laser treatment and cryotherapy technologies.
The combined company will employ over 550 individuals nationwide.
About Altaris Capital Partners, LLC
Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Managing $1.3 billion of equity capital, Altaris invests in businesses that meet clearly defined healthcare needs and leverages its extensive industry knowledge and relationships to accelerate growth and value appreciation. Altaris is based in New York, NY. For more information visit www.altariscap.com.
About HealthTronics, Inc.
HealthTronics, Inc., established in 1989 and headquartered in Austin, TX, provides mobile equipment services and medical devices to the urology industry. The company partners with physician groups to facilitate equipment ownership and to provide logistical support for mobile lithotripsy, laser and cryoablation systems. In addition, HealthTronics offers a comprehensive line of cryoablation devices with a variety of therapeutic applications. For more information visit www.healthtronics.com.

Quantum Health to Speak at The Conference Board’s 16th Annual Employee Health Care Conference

Columbus, OH Mar 3, 2016 – Quantum Health Founder and Chief Executive Officer Kara Trott teams up with Pam Hannon, Director of the Benefits Practice Center for Abbott, and Bob Ihrie, Senior Vice President of Compensation and Benefits for Lowe’s, to present at The Conference Board’s 16th Annual Employee Health Care Conference that will be held March 10-11, 2016 at the New York Marriott Marquis in New York City. Kara will present with Matthew Eurey, Director of Benefits for Lowe’s, at the San Diego conference on March 17-18 at the Hilton San Diego Bayfront in San Diego, CA.
The team will present “Are We There Yet? On the Journey to Better Health Care.” In this discussion, benefits executives will reveal their breakthrough approaches to benefits delivery. These approaches lead to an increase in member engagement, exceptional health care experience and a more positive overall outcome. Hannon, Ihrie and Eurey will discuss the challenges they faced and the way they are managing their health plan costs, as well as how they are measuring their success.
Live streaming of the New York event will be held March 11, 8:55AM – 9:45AM.
http://pages.conference-board.org/EHCCNY_LIVESTREAM_LP.html
About Quantum Health
Quantum Health is an award-winning care coordination and consumer navigation company serving the needs of self-insured public and private employers across the United States since 1999. With a background in consumer behavior and a deep understanding of how real people experience healthcare, Quantum Health has a proven history of improving the efficiency of clients’ benefits plans while maintaining industry-leading satisfaction rates and claims savings. Based in Columbus, Ohio, Quantum Health has been recognized on the Inc. 5000 as one of the fastest-growing privately held companies for the past eight consecutive years (2008-2015), listed as one of the 50 Fastest Growing Women Owned/Led Companies by the Women Presidents’ Organization and has been listed as both a FORTUNE Magazine Great Place to Work® and an Entrepreneur Magazine Great Place to Work®. Learn more at Quantum-Health.com, and connect with us on Twitter (@QuantumHealth1), and LinkedIn (Company: Quantum Health).

CATS (Container Automated Tracking System)

Dayton, OH Feb 9, 2016 – Determining the optimum lease arrangements for active RKN containers and keeping track of a leased RKN portfolio can be a real headache for logistics companies shipping biologics and other temperature-sensitive products. Using the new CATS Customer Portal from CSafe allows container lessees to manage and oversee their RKN inventory from the comfort of their desks. The CATS data system allows authorized users instant and unlimited access to RKN log file decryption and charts at no cost.
Nearly two years in the making, the innovative CATS customer portal provides users with at-a-glance lease status including active and historical container status, RKN service history, testing/certification data and temperature verification dates as well as a host of industry and CSafe product information including user manuals and relevant SOPs.
Mark Mohr, CSafe Global’s Director of Customer Support and Partner Management says, “Access to the information in real-time closes the loop in the data chain when it comes to track and trace and regulatory compliance. By accessing validation and conformance data housed within the CATS system, CSafe authorized users can be assured of the quality of the equipment under lease.”
All customer account information is held on a secure server as encrypted data which is available for download as pre-formatted and ad-hoc reports as well as charts for offline analysis, processing and action. Content access can be controlled on an individual level, allowing restriction of user access to content based on specific business requirements.
“In developing the CATS system we listened to the advice from our MLA partners to ensure it was as useful and user-friendly as possible,” says Mr. Mohr. “The system has been thoroughly beta-tested with select customers over an eight-month period to ensure it is intuitive to use, secure and bug-free.”
Unlimited access to the CATS Container Automated Tracking System is free of charge to all CSafe Global’s Master Lease Agreement holders.

CMP Pharma and Generic Specialty Pharma Sign Product Development Agreement

Farmville, NC Feb 5, 2016 – CMP Pharma, Inc. of Farmville, NC and Generic Specialty Pharma Ltd. (GSP) of Dublin, Ireland have reached an agreement to partner on the development of a new prescription product (NDA). The product under development will be available in a sterile vial and represents CMP’s first product in an injectable dosage form.
Commenting on the agreement, CMP Pharma’s CEO Gerald Sakowski said “This agreement reinforces our commitment to bring new niche products to market. We are pleased that this product provides CMP a unique opportunity to expand into a new dosage form area while at the same time provides an important product to our current acute care customer base”.
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and oral liquid pharmaceutical products. The company was founded in the early 1980s around the development of a ready-to-use liquid for sodium polystyrene sulfonate, a prescription drug used for the treatment of hyperkalemia.
Generic Specialty Pharma is a privately owned pharmaceutical company established in 2012, headquartered in Dublin, Ireland. GSP and its affiliates markets products through partners in more than 30 countries throughout the world with a strong focus on injectables.

Investment in Minnetronix

New York, NY: Altaris Capital Partners, LLC announces an investment in Minnetronix, Inc.
Minnetronix provides design, development and manufacturing services to the medical technology industry. The Company is also leveraging its engineering expertise to develop a platform of proprietary technologies that possess clinical breakthrough potential. Altaris is partnering with the Minnetronix management team and employees to support the future growth of the Company.
Altaris Capital Partners was advised on this transaction by Piper Jaffray and Schiff Hardin LLP.
About Altaris Capital Partners, LLC
Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Managing $1.3 billion of equity capital, Altaris invests in businesses that meet clearly defined healthcare needs and leverages its extensive industry knowledge and relationships to accelerate growth and value appreciation. Altaris is based in New York, NY. www.altariscap.com
About Minnetronix, Inc.
Minnetronix is a medical technology and innovation company with deep expertise in electronic and electromechanical devices. Founded in 1996, the company creates new technologies and therapies that solve unmet clinical and business needs for patients and medical device companies. Minnetronix is FDA Registered and ISO 13485 Certified. www.minnetronix.com

CSafe Global Continues to Expand European Product Offering

Dayton, OH Jan 13, 2016 – CSafe Global, the only provider of a full-line of active and passive cold chain packaging solutions, will be exhibiting an approved CE compliant small active container and several temperature-management mobile couriers at the 15th Annual IQPC Temperature Controlled Logistics Europe event in Frankfurt on 26/27 Jan 2016.
The 2016 IQPC cold chain conference will be the European launch platform for a high-performance portable CE approved refrigerated/frozen container for transporting sensitive biologic, vaccine and blood products as well as an offering enhancement to the existing AcuTemp brand couriers. The company will be displaying their active, passive packaging and passive mobile handheld couriers at stand No. 27.
According to Brian Kohr, President and CEO at CSafe Global, “The success of these CSafe Global products over the past year has been exceptional as the market adjusts to new regulatory requirements and to the special transportation requirements of high-value, environmentally-sensitive, bio-pharmaceuticals. In addition, our successful pursuit of collaborative partnerships with key customers and suppliers has allowed us to steadily expand our reach into developing countries and new locations.
“Particularly we have seen pharma shippers increasingly adopt a ‘total cost of ownership’ approach where the true lifetime costs of cool chain solutions are taken into consideration. With our extensive range of both active and passive solutions, from full-size ULDs to smaller hand-portable units, and with a variety of buying and leasing options available, CSafe have been able to capitalise strongly on the growing emphasis on cost rather than price.”
CSafe Global invites pharmaceutical industry shippers and logistics specialists to IQPC Europe, January 26th and 27th, at the Frankfurt Messe, Booth 27.

Ci Medical Technologies Sold to Technimark

New York, NY: Altaris Capital Partners, LLC is pleased to announce that Ci Medical Technologies has been sold to Technimark.
Ci Medical Technologies is a manufacturer of injection-molded plastic components for precision medical devices. The company provides its blue-chip OEM customers with design, prototyping, assembly, packaging and distribution services through its manufacturing facilities in North America and Europe. Altaris acquired Ci Medical Technologies in 2006 and, during its investment period, supported the company as it expanded its capabilities, service offerings and geographic footprint to better serve its customers worldwide.
Ci Medical Technologies and Altaris Capital Partners were advised on this transaction by Lincoln International LLC and Schiff Hardin LLP.
About Altaris Capital Partners, LLC
Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Managing $1.3 billion of equity capital, Altaris invests in businesses that meet clearly defined healthcare needs and leverages its extensive industry knowledge and relationships to accelerate growth and value appreciation. Altaris is based in New York, NY. www.altariscap.com
About Ci Medical Technologies
Ci Medical Technologies is a full-service contract manufacturer of injection-molded components used in medical devices and pharmaceutical products. The company’s production facilities are located in Latrobe, Pennsylvania; El Paso, Texas; Ponce, Puerto Rico; and Durham, U.K.; and its third-party logistics facility is in Ciudad Juarez, Mexico. Ci Medical Technologies’ operations meet all applicable ANSI and ISO standards, and FDA regulations, and reflect the best practices of Lean Six Sigma management. Ci Medical Technologies was founded in 1971 and is headquartered in Latrobe, PA. www.cimedtech.com

Sale of IMG

New York, NY: Altaris Capital Partners, LLC is pleased to announce that International Medical Group (IMG) has been sold to funds managed by ABRY Partners.
IMG is a leader in the global medical insurance and assistance services market. Altaris acquired IMG in 2012 and, during its investment period, supported the company as it expanded its management team, strengthened its risk-sharing partnerships and grew its international footprint to serve members in more than 200 countries.
IMG and Altaris Capital Partners were advised on this transaction by Greenhill & Co. and Schiff Hardin LLP.
About Altaris Capital Partners, LLC
Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Managing $1.3 billion of equity capital, Altaris invests in businesses that meet clearly defined healthcare needs and leverages its extensive industry knowledge and relationships to accelerate growth and value appreciation. Altaris is based in New York, NY. www.altariscap.com
About International Medical Group
International Medical Group (IMG) is a provider of high quality global medical insurance benefits focused on the international health and travel insurance markets. Founded in 1989 as a managing general underwriter, IMG has provided insurance solutions to millions of U.S. and non-U.S. citizens traveling or living abroad. IMG is headquartered in Indianapolis, IN. www.imglobal.com

Revolutionary M2S Preview® product reaches milestone with 300,000 Cardiovascular 3D Imaging Reconstructions

West Lebanon, NH Oct 13, 2015 – M2S®, Inc., a leader and innovator in technology for quality improvement in healthcare has now completed over 300,000 high quality cardiovascular 3D reconstructions for clients. M2S has provided cardiovascular imaging services and Preview® surgical planning software to over 400 hospitals and 1,000 vascular surgeons and surgical teams, both in the United States, and internationally.
Preview has helped to revolutionize the way in which cardiovascular disease is evaluated, treated and monitored. It provides specialized hyper-accurate measurements, provides treatment planning assistance, and is an integral part of the follow up surveillance and long-term care for high-risk patients. The images received for 3D Preview reconstruction and clinical trial assessment are primarily CT’s, but MRA’s, X-rays and ultrasounds are also used to develop the most comprehensive 3D reconstruction of the relevant anatomy. The average data set provided to M2S for Preview purposes is approximately 1,000 images, resulting in a database of close to 300 million individual medical images.
Founded in 1997, M2S (previously Medical Media Systems, Inc) started as a small R&D firm. In 2000, Preview was granted approval from the FDA as a Class II medical device, which allowed the company to begin providing products and services on a commercial basis. The usage of Preview has grown in the vascular medical community, and the 300,000 Preview reconstructions have been created over a span of 15 years.
Greg Lange, President and CEO at M2S, says “From the initial development of devices for EVAR, M2S has been helping surgeons with cardiovascular case planning and patient surveillance. Our Preview product and PEMS system provide exceptional tools for understanding the patient’s unique anatomy, visualizing graft placement, determining the best treatment plan and managing patients over time. We are incredibly proud to have touched this many lives and enabled the best clinical outcomes.”
Many vascular surgeons are long-term Preview users, and have integrated it into their case planning year after year. “M2S has always provided a high quality product enabling long term surveillance projects, such as SVS VQI, and other critical study support including core lab analysis,” said Dr. Rod White, who has been using M2S since its inception. “We rely on the data provided by M2S for routine clinical care and surveillance, and have benefited by having complex case planning provided to support commercial and Physician Sponsored IDE development and data analysis. I am also impressed by the level of dedication and expertise demonstrated by the M2s employees – consistently reliable and always focused on patient care.”